ecancermedicalscience最新文献

{"title":"Prevalence of bacterial vaginosis, sexually transmitted infections and their association with HPV infections in asymptomatic women attending antenatal care in Ethiopia.","authors":"Johanna M A Klein, Isabel Runge, Ann-Katrin Pannen, Tariku Wakuma, Semaw Ferede Abera, Adamu Adissie, Susanne Unverzagt, Markus Schmitt, Tim Waterboer, Daniela Höfler, Christoph Thomssen, Eva Johanna Kantelhardt","doi":"10.3332/ecancer.2024.1783","DOIUrl":"10.3332/ecancer.2024.1783","url":null,"abstract":"<p><p>Sexually transmitted infections (STIs) and human papillomavirus (HPV) infections are common among women of reproductive age and can lead to infertility, adverse pregnancy outcomes, neonatal infections and cervical cancer. In countries with limited medical coverage, untreated infections contribute to high morbidity. This study aimed to expand the current knowledge on the prevalence of bacterial vaginosis (BV) and STIs in pregnant Ethiopian women and assess the association of these conditions with HPV infections. Socio-demographic data and vaginal lavage samples were collected from 779 asymptomatic women aged 18 to 45 years (median age, 25.9 years) attending antenatal care in seven centres across Ethiopia. Multiplex polymerase chain reaction was used to test for BV, <i>Chlamydia trachomatis</i>, <i>Trichomonas vaginalis</i>, <i>Neisseria gonorrhoeae</i>, herpes simplex virus types 1 and 2 (HSV-1/2), <i>Mycoplasma</i>, <i>Ureaplasma</i>, <i>Candida species</i> and HPV. Overall, 26.8% (95% confidence interval (CI): 23.7-29.9) of women tested positive for BV or one of the following STIs: <i>C. trachomatis</i>, <i>T. vaginalis</i>, <i>N. gonorrhoeae</i>, <i>Mycoplasma genitalium</i>, HSV-1/2 or <i>Ureaplasma urealyticum</i>. Additionally, 22.1% tested positive for at least one high-risk HPV type. <i>Chlamydia trachomatis</i> and HSV-2 were significantly more common among women who were positive for HPV and high-risk HPV. This study reveals a high prevalence of asymptomatic pregnant women who are positive for BV, STIs or HPV, putting them at risk of adverse pregnancy outcomes, secondary infertility or cervical cancer in a country with limited medical coverage. Screening and treating these women could be crucial in reducing morbidity.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1783"},"PeriodicalIF":1.2,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The regional cancer spectrum in Uganda: a population-based cancer survey by sub-regions (2017-2020).","authors":"Francis Okongo, Catherine Amuge, Alfred Jatho, Nixon Niyonzima, David Martin Ogwang, Jackson Orem","doi":"10.3332/ecancer.2024.1782","DOIUrl":"10.3332/ecancer.2024.1782","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Accurate estimation of the burden of cancer in developing countries is a major public health concern for cancer prevention and control because of the limited coverage of population-based cancer registries (PBCRs). The cancer registration coverage status of Uganda was 11.90% and was not uniformly distributed in all regions of Uganda. This population-based survey was conducted to assess the burden of cancer in all the sub-regions of Uganda by site, sex and age group to accurately determine the cancer profile of Uganda by sub-region for a tailored intervention to mitigate cancer risk factors and burden.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;This study used existing administrative units of Uganda from which 55 districts emerged, forming 10 sub-regions as satellite population-based cancer registry study sites. Data on newly diagnosed cancer cases were retrospectively collected for the period 2017-2020 using a cancer notification form, entered into CanReg5 Software, exported to spreadsheets and univariate analysis was performed to determine the cancer spectrum, their proportions and crude rates by site, sex, age group and geographical location.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;A total of 25,576 cancer cases were registered, up to 14,322 (56%) were in females and, male cancers were 11,254 (44%). The top five female cancers in all the sub-regions included cervical cancer (43%, &lt;i&gt;n&lt;/i&gt; = 6,190), breast (22%, &lt;i&gt;n&lt;/i&gt; = 3,200), esophagus (5.6%, &lt;i&gt;n&lt;/i&gt; = 800), ovary (5.2%, &lt;i&gt;n&lt;/i&gt; = 746), Kaposi Sarcoma (KS) (4.7%, &lt;i&gt;n&lt;/i&gt; = 666) and other less common cancers (18.5%, &lt;i&gt;n&lt;/i&gt; = 2,720). In males, the top five cancers included prostate cancer 25.1 % (&lt;i&gt;n&lt;/i&gt; = 2,820), esophagus 15.1% (&lt;i&gt;n&lt;/i&gt; = 1,704), KS 12.4% (&lt;i&gt;n&lt;/i&gt; = 1,395), liver 8.8% (&lt;i&gt;n&lt;/i&gt; = 989) and stomach 4.8% (&lt;i&gt;n&lt;/i&gt; = 539), with other less common male cancers accounting for 33.8% (&lt;i&gt;n&lt;/i&gt; = 3,807).In all the sub-regions of Uganda, cancers of the esophagus, liver and KS are common in both males and females, but the number of males with these cancers is twice that of their female counterparts. In Rwenzori, Kigezi and Bugishu sub-Regions, there seems to be an increased risk of developing other skin cancers in females, while stomach cancers have been reported in both males and females. Most of the other sub-regions register emerging cases of only ovarian cancer in females. In children, the top three cancers included lymphoma, 33.9% (&lt;i&gt;n&lt;/i&gt; = 653); soft tissue sarcomas, 20.8% (&lt;i&gt;n&lt;/i&gt; = 400); malignant bone tumors, 15.8% (&lt;i&gt;n&lt;/i&gt; = 305); myeloid-type leukemia, 13.8% (&lt;i&gt;n&lt;/i&gt; = 265); and the other less common childhood cancers combined, 15.7% (&lt;i&gt;n&lt;/i&gt; = 303). The proportion of childhood cancers is higher in the male child compared to the female at a ratio of 1.3:1.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions: &lt;/strong&gt;The sub-regional cancer spectrum in Uganda ranges from cervical cancer to breast, esophageal, ovarian and KS in females. Male cancers include prostate, esophage","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1782"},"PeriodicalIF":1.2,"publicationDate":"2024-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can combined paravertebral and erector spinae block provide perioperative analgesia for mastectomy with LD flap reconstruction surgery? An observational study.","authors":"Arunangshu Chakraborty, Sanjit Agrawal, Shiladitya Bose, Rosina Ahmed, Rakhi Khemka","doi":"10.3332/ecancer.2024.1781","DOIUrl":"10.3332/ecancer.2024.1781","url":null,"abstract":"<p><strong>Background: </strong>Mastectomy and breast reconstruction with latissimus dorsi myocutaneous flap (LDF) is a major surgery that covers eight or more dermatomes causing severe pain in the postoperative period.</p><p><strong>Objectives: </strong>We evaluated the analgesic effect of a hybrid technique of ultrasound-guided combined thoracic paravertebral block (TPVB) and erector spinae plane block (ESPB) in a single needle pass in ten consecutive patients scheduled for mastectomy with LDF reconstruction as a part of a multimodal analgesia regimen.</p><p><strong>Design: </strong>Prospective observational study.</p><p><strong>Setting: </strong>A tertiary-level cancer hospital in Eastern India. The study was conducted between 01/09/2023 and 20/12/2023.</p><p><strong>Patients: </strong>10 consecutive consenting female patients of age between 18 and 75 years suffering from breast cancer, scheduled for a mastectomy with LDF reconstruction were recruited in this study, excluding patients with body mass index more than 40, coagulopathy or thrombocytopenia, skin conditions such as dermatitis, infection and so on, and known allergy to local anaesthetics (LAs).</p><p><strong>Interventions: </strong>The recruited patients received an ultrasound-guided combined thoracic paravertebral and erector spinae (COMPARES) block at the third thoracic (T3) level in a single needle pass, with 10 mL in the TPVB and 30 mL in the ESPB compartment, respectively, in a cephalad to caudad approach before induction of general anaesthesia.</p><p><strong>Main outcome measures: </strong>The primary endpoint was pain score at 9:00 am on postoperative day one. Other outcome measures were pain scores at postoperative hours 0 (immediately after awakening from general anaesthesia), 4, 8 and 12, postoperative nausea vomiting, requirement of rescue analgesics and pain score on shoulder movements on postoperative day one.</p><p><strong>Results: </strong>Median (range) resting pain scores at 0, 4, 8 and 24 hours were 1.5 (0-5), 2.5 (0-4), 2.5 (2-5) and 3 (2-4), and dynamic pain score on shoulder mobilization on postoperative day one morning was 3 (2-6). Only one patient required rescue analgesia.</p><p><strong>Conclusions: </strong>We found the technique inexpensive and potentially useful, but difficult in obese and short-statured patients due to increased depth and narrowing of the intertransverse space. This technique should be further evaluated in a randomised controlled trial.</p><p><strong>Trial registration: </strong>This trial was registered with the Clinical Trials Registry of India with the registration number CTRI/2023/08/057119.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1781"},"PeriodicalIF":1.2,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489115/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathological features associated with CD44 and CD63 expression in breast cancer.","authors":"Carlos A Castaneda, Miluska Castillo, Joselyn Sanchez, Luis Bernabe, Katherin Tello, Nancy Suarez, Raul Alatrista, Ximena Quiroz-Gil, Alexandra Granda-Oblitas, Javier Enciso, Nathaly Enciso, Henry L Gomez","doi":"10.3332/ecancer.2024.1779","DOIUrl":"10.3332/ecancer.2024.1779","url":null,"abstract":"<p><strong>Background: </strong>CD44 is a cell-surface transmembrane glycoprotein that participates in the regulation of many cellular processes, including cell division, adhesion, migration and stem-like characteristics. CD63 is involved in the exocytosis process.</p><p><strong>Objective: </strong>To evaluate the relationship between CD44 and CD63 expression and clinicopathological features, including tumor-infiltrating lymphocytes (TILs), phosphoinositide 3-kinase (PIK3CA) mutation and survival.</p><p><strong>Methodology: </strong>CD44 and CD63 were stained in samples from 101 breast cancer cases from Peruvian women.</p><p><strong>Results: </strong>Median age was 52 years, most were most were grade-3 (68%), estrogen receptor (ER)+ (64%) and stage II-III (92%). Median ki67 was 30%, median stromal TIL was 30% and <i>PIK3CA</i> mutation was found in 49%. Longer survival was associated with earlier stages (<i>p</i> = 0.016), lower ki67 (<i>p</i> = 0.023), ER+ (<i>p</i> = 0.034), luminal phenotype (<i>p</i> = 0.029) and recurrence (<i>p</i> < 0.001). CD44 was classified as high cell density staining in 57% and high intensity in 55%. High CD44 density was associated with younger age (<i>p</i> = 0.043), triple-negative phenotype (<i>p</i> = 0.035) and shorter survival (<i>p</i> = 0.005). High CD44 expression was associated with short survival (<i>p</i> = 0.005). High CD63 cell density was found in 56% of cases and was associated with ER-positive (<i>p</i> = 0.045), low TIL levels (<i>p</i> = 0.007), Luminal-A (<i>p</i> = 0.015) and low CD44 intensity (<i>p</i> = 0.032).</p><p><strong>Conclusion: </strong>CD44 expression was associated with aggressive features and low CD63 density staining.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1779"},"PeriodicalIF":1.2,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489100/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"African colorectal cancer burden in 2022 and projections to 2050.","authors":"Mounoume Lobe Irma Louise Virginie, Qiu Zhao, Lan Liu","doi":"10.3332/ecancer.2024.1780","DOIUrl":"10.3332/ecancer.2024.1780","url":null,"abstract":"<p><strong>Introduction: </strong>The burden of colorectal cancer (CRC) is on a rapid increase on the African continent, yet grossly under reported. Herein, we provide and updated estimates of CRC burden (incidence and mortality) across Africa as of 2022, and make crucial predictions to 2050.</p><p><strong>Methods: </strong>We gathered information on CRC incidence and mortality from the GLOBOCAN 2022 database, which covers 185 countries. The age-standardised incidence and mortality rates (ASRs) per 100,000 person-years were determined. Cases and deaths up to 2050 were estimated using 2022 incidence and mortality rates.</p><p><strong>Results: </strong>In 2022, an estimated 70,428 cases and 46,087 mortalities due to CRC were recorded across the African continent. Africa's ASRs for CRC incidence and mortality were 8.2 and 5.6 per 100,000 population, respectively, and were highest in North Africa followed by East Africa. At national levels, CRC ranked in the top four of the most commonly diagnosed cancers in more than half (56%) of African countries. ASRs of both incidence and mortality were higher among males than females. New cases are predicted to increase by 139.7% (from 70,428 in 2022 to 168,683 in 2050) at the current incidence rate. Similarly, mortalities will increase by 155.2% (from 46,061 in 2022 to 117,568 in 2050).</p><p><strong>Conclusion: </strong>CRC remains a major cause of morbidity and mortality in many African countries, and the number of new cases and deaths is predicted to rise significantly by 2050. Efforts to reduce the incidence of preventable CRC cases should be prioritised.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1780"},"PeriodicalIF":1.2,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors influencing tobacco quitting: findings from National Tobacco-Quitline Services, Mumbai, India.","authors":"Atul Budukh, Sharyu Mhamane, Sonali Bagal, Priyal Chakravarti, Ganesh Ogale, Radhika Sharma, Manisha Yadav, Sushama Saoba, Suvarna Gore, Pankaj Chaturvedi","doi":"10.3332/ecancer.2024.1777","DOIUrl":"10.3332/ecancer.2024.1777","url":null,"abstract":"<p><p>The Government of India established National Tobacco Quitline Services (NTQLS) to provide free and effective telephonic counselling to help people quit tobacco. The objective of the paper is to present the data of tobacco quitters who quit tobacco through NTQLS, Mumbai, in the years 2021-2022 and the factors that influenced tobacco quitting. This is a prospective study where individuals willing to quit tobacco utilised NTQLS. Effective counselling was provided and was followed up. Multiple logistic regression analysis was conducted. Tobacco quitting is the dependent variable while sociodemographic characteristics, tobacco consumption habits, previous quit attempts, alcohol consumption, other substance use and co-morbidity were independent variables. In the years 2021-2022, a total of 448,893 calls hit the system. Of these, 127,163 (28.3%) calls were attended. Of the attended calls, a quit date was set for 21,504 calls (16.9%); of these, 8,276 (38.5%) callers quit tobacco. Individuals with no previous quit attempts [OR: 1.48, 95% confidence interval (CI): 1.25-1.75], never consumed alcohol (OR: 1.37, 95%CI: 1.2-1.56), consumed tobacco within 6-30 minutes (OR: 1.29, 95% CI: 1.12-1.49) and 30-60 minutes after waking up (OR: 1.26, 95% CI: 1.05-1.51) had higher quitting rates. While, female callers (OR: 0.59, 95% CI: 0.35-0.99), private sector workers (OR: 0.70, 95% CI: 0.61-0.81), individuals consuming more than ten tobacco units/packets (OR: 0.70, 95% CI: 0.61-0.79), tobacco use more than 10 years (OR: 0.85, 95% CI: 0.73-0.97), expenditure of more than 5,000 rupees on tobacco (OR: 0.58, 95% CI: 0.44-0.77) and those with no known co-morbid conditions (OR: 0.8, 95% CI: 0.71-0.91) were less likely to quit tobacco. Reduced tobacco consumption will inadvertently reduce the non-communicable disease (NCD) burden and help in achieving the sustainable development goals related to tobacco control and NCD. Quitline plays an important role in tobacco control.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1777"},"PeriodicalIF":1.2,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489103/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporating a mobile application to support communication about HPV testing among women and professionals: barriers and facilitators from the perspective of health professionals in a middle- and low-income setting in Argentina.","authors":"Lucila Szwarc, Paula Frejdkes, Victoria Sánchez Antelo, Melisa Paolino, Silvina Arrossi","doi":"10.3332/ecancer.2024.1778","DOIUrl":"10.3332/ecancer.2024.1778","url":null,"abstract":"<p><strong>Introduction: </strong>The delivery of positive Human papillomavirus (HPV) test results can have a psychosocial impact and act as a barrier for women to continue the cervical cancer (CC) prevention process. A previous formative research based on a woman's perspective indicated that a mobile app could be an acceptable and appropriate tool to help women obtain information and reduce fears related to a positive result. Based on these findings, we developed an app-based intervention that would function as a support for professionals who offer the HPV test and communicate their results. We report data on the perceptions of healthcare providers regarding the barriers and facilitators to the incorporation, in a low and middle-income context.</p><p><strong>Methods: </strong>Qualitative study based on individual semi-structured interviews with health professionals. All the professionals (<i>n</i> =13) took HPV and Pap test samples and provided information on HPV testing, in the public health system of Ituzaingó, Greater Buenos Aires, Argentina. The themes explored were selected and analysed using domains and constructs of Consolidated Framework for Implementation Research (CFIR).</p><p><strong>Results: </strong>Practitioners had a positive assessment of the intervention through most included constructs: adaptability, compatibility, complexity, relative advantage, belief in the validity and robustness of the intervention, innovation source and knowledge and beliefs about the intervention. However, some potential barriers were also identified including: adaptability, tensions for change, relative priority and leadership engagement. Practitioners conditioned the intervention's success to specific adjustments of the app (weight and interface usability), legitimmated institutions' support, and clear and sustained health authorities' commitment and directions.</p><p><strong>Conclusion: </strong>Health professionals had a positive assessment of implementing an app to support the HPV test communication and information provision process, although they conditioned its effectiveness to specific adjustments. The results allow us to identify and develop recommendations for the app to be implemented effectively and sustained over time. The findings of this study have important implications not only for Argentina, but also for other low and middle-income countries, given that the implementation could be adapted, with the aim of improving communication between patients and health institutions in the CC prevention process.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1778"},"PeriodicalIF":1.2,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pattern of care and treatment outcomes of metastatic non-clear cell kidney cancer: a single centre experience from India.","authors":"Somnath Roy, Sreejata Raychaudhuri, Bivas Biswas, Deepak Dabkara, Arnab Bhattacherjee, Sandip Ganguly, Joydeep Ghosh, Yesha Sandipbhai Patel, Souhita Pal, Jagriti Karmakar, Anindita Mitra, Sujoy Gupta","doi":"10.3332/ecancer.2024.1775","DOIUrl":"10.3332/ecancer.2024.1775","url":null,"abstract":"<p><strong>Background: </strong>Non-clear-cell renal cell carcinoma (nccRCC) refers to a rare diverse heterogeneous group of tumours; usually treated with immune check point inhibitors and or tyrosine kinase inhibitors (TKIs). Prospective large-scale data from Asian countries is limited.</p><p><strong>Methods: </strong>This is a retrospective study of patients with metastatic nccRCC treated at Tata Medical Centre, Kolkata, India, from 2012 to 2022. Demographic profiles, histologic subtypes, treatment details, response to therapy (by response evaluation criteria in solid tumours (RECIST v1.1)) and survival status were captured from electronic medical records (EMRs) of hospitals up till May 2023. Kaplan Meier methods were estimated to assess progression-free survival (PFS) and overall survival (OS).</p><p><strong>Results: </strong>A total of 89 consecutive patients were screened for this study, 24 were excluded due to inadequate data in EMR. 65 patients were included in the final analysis, with a median age at diagnosis of 59 years (range 20-84) of which 81% were male. Histologic subtypes comprised of 43% papillary, 31% clear cell with mixed histology, 3% sarcomatoid and 23% others including chromophobe, mucinous-tubular, spindle cell, oncocytic, medullary, poorly differentiated and rhabdoid). The most common site of metastasis was the lung 62% (<i>n</i> = 40) followed by non-regional nodes 32%, bone 26% and liver 14%. 15% patients presented with haematuria and 62% underwent nephrectomy prior to systemic therapy. The majority received pazopanib 46% (<i>n</i> = 30), chemotherapy 20% (<i>n</i> = 13) including bevacizumab plus erlotinib, sunitinib 15% (<i>n</i> = 10) or cabozantinib 14% (<i>n</i> = 9). Only 3(5%) patients received nivolumab plus cabozantinib combination. Response to treatment showed complete response in 1.5%, partial response in 20%, stable disease in 51% and progressive disease in 23% as per RECIST v1.1. 17 patients required dose reduction and interruption due to adverse effects and 33% (<i>n</i> = 22) received second-line therapy with nivolumab 18% (<i>n</i> = 4), axitinib and everolimus among others. After a median follow up of 44 months, the median PFS was 13 months (95%CI 7.2-18.9) and the median OS was 17 months (95%CI 12.1-22.1) for the entire cohort.</p><p><strong>Conclusion: </strong>The overall response and survival for metastatic nccRCC was relatively better in comparison with published data, despite the limited number of patients treated with ICIs due to cost and access barriers.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1775"},"PeriodicalIF":1.2,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489090/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tyrosine crystal deposition in pleomorphic adenoma: a rare presentation in a male smoker with long-term follow-up.","authors":"Sandhya Tamgadge, Gokul Venkateshwar, Treville Pereira, Avinash Tamgadge, Simran Pethani","doi":"10.3332/ecancer.2024.1776","DOIUrl":"10.3332/ecancer.2024.1776","url":null,"abstract":"<p><p>This case report presents the diagnosis and management of a pleomorphic adenoma in a 55-year-old male smoker with a habit of smoking tobacco for 6 years. The patient presented with a chief complaint of swelling in the posterior palatal region. Clinical examination revealed a well-circumscribed, non-tender, firm swelling in the palatal region. An incisional biopsy followed by surgical excision was performed, and histopathological evaluation confirmed the diagnosis of pleomorphic adenoma. Tyrosine crystals were observed within the tumour stroma, providing additional diagnostic insight. A 10-year post-operative follow-up revealed no recurrence of the lesion.</p>","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1776"},"PeriodicalIF":1.2,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A physiotherapists perspective of a geriatric clinic in a tertiary oncology centre.","authors":"Ankita Chitre, Akhil Kapoor, Bipinesh Sansar, Anuj Gupta, Praveen Lakshmanamurthy, Somnath Dey, Kunal Vinayak, Ajit Sahoo, Navneet Kaur, Sumaiya Azeem, Dipti Kadu, Akash Anand Shrivastav","doi":"10.3332/ecancer.2024.1774","DOIUrl":"10.3332/ecancer.2024.1774","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aims and objectives: &lt;/strong&gt;To analyse various domains amongst the geriatric population such as age, gender, body mass index (BMI), comorbidities, type of cancer and use of assistive devices, and find a correlation between the outcome measures such as short physical performance battery (SPPB) and performance-oriented mobility assessment (POMA).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methodology: &lt;/strong&gt;Patients above 60 years were screened and further referred to the physiotherapy department. A brief history was recorded to retrieve the demographic data such as name, age, gender, height, weight, BMI, hand dominance, diagnosis, previous investigations are done, comorbidities if any present, use of assistive devices if required and in case any previous oncological treatment has been delivered. Various outcome measures were administered such as POMA, SPPB, 6 minutes walk test (6 MWT) and numerical rating for fatigue. The interpretations were noted on a case report sheet and the appropriate interventions for the deficits were delivered to the patient. Also, the patients were asked to carry on the necessary investigation (if required) and get back to the physiotherapy OPD. No follow-up is required by the patients as this was a retrospective single-endpoint study.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results and analysis: &lt;/strong&gt;The descriptive analysis was done by using R software (version 4.2.3). The main objective was to analyse the variables descriptively using numbers and percentages. The correlation between 2 outcome measures: SPPB and POMA was assessed using Spearman's rank correlation.All the 100 patients had solid tumour malignancies, commonly GI (37%), thoracic (18%), breast (17%), H and N (13%), uro-oncology (11%) and gynecology (4%). The median age was 70 years (range, 60-88). The median BMI was 22.10 (IQR, 19.40-24.77). Among 100 patients, comorbidities were found in most of the patients, most commonly hypertension (35%), diabetes mellitus (20%), heart disease (9%) and other diseases (8%). Out of 100 patients, 15% of them used assistive devices but the remaining 85% of patients did not require any assistive devices. Different outcome measures were also assessed for understanding the patients' risk in different categories. On assessing POMA, most of the patients had a medium risk of fall (49%), followed by high risk (31%) and low risk (14%). On assessing SPPB, most of the patients had low risk (41%), followed by medium risk (31%) and high risk (28%). The aerobic capacity of patients was assessed using 6 MWT (walking capacity) which showed that most of them had a severe reduction in aerobic capacity (37%) followed by moderation reduction (28%), good aerobic capacity (25%) and mild reduction (10%). The treatment required by the patients involved most commonly LL strengthening (71; 30.6%) and aerobic conditioning (67; 28.9%) and the least was brisk walking (4; 1.72%) and UL strengthening (2; 0.86%).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Commonly deranged domains included fatig","PeriodicalId":11460,"journal":{"name":"ecancermedicalscience","volume":"18 ","pages":"1774"},"PeriodicalIF":1.2,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142460626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}